Related Experiment Videos
An Abeta sequestration approach using non-antibody Abeta binding agents
Yasuji Matsuoka1, Li Shao, Manik Debnath
1Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA. ym56@georgetown.edu
Current Alzheimer Research
|June 25, 2005
Summary
Investigating amyloid beta (Abeta) sequestration for Alzheimer's disease (AD), this study found Congo red derivatives ineffective. Optimized Abeta binding agents with high affinity are needed for the peripheral sink approach.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Amyloid beta (Abeta) is implicated in Alzheimer's disease (AD) pathogenesis.
- Abeta-lowering strategies, including active immunization, are under investigation.
- Two proposed mechanisms for Abeta reduction are microglial phagocytosis and peripheral sink (Abeta sequestration).
Purpose of the Study:
- To test the hypothesis that Abeta sequestration alone, without immune modulation, can reduce brain Abeta load.
- To evaluate the efficacy of three Congo red derivatives as Abeta binding agents for peripheral administration.
Main Methods:
- Testing three Congo red derivatives in Abeta plaque-forming mice.
- Administering compounds peripherally for three weeks.
- Assessing changes in brain Abeta load.
Main Results:
- Peripheral administration of Congo red derivatives did not substantially alter brain Abeta load.
- The tested compounds showed insufficient efficacy for reducing brain Abeta.
Conclusions:
- Abeta sequestration without immune modulation requires optimized binding agents.
- High-affinity binding agents targeting soluble Abeta are necessary for effective sequestration therapy.